Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide plus ADT in Metastatic Hormone-Sensitive Prostate Cancer
NCT05059236Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2021
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Started Nov 2021; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05059236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05059236.